Foundations of theranostics
Radioligand therapy (RLT) and radioligand imaging (RLI) offer a novel, theranostic approach to targeting and treating certain types of cancer.1 This section of the Novartis RLT Institute is designed to help health care professionals (HCPs) understand the basic scientific foundations of RLT. By focusing on the science, we aim to demystify radiation and safety concerns and build confidence in offering patients this approach to precision medicine in cancer.
An emerging pillar of oncology care
An emerging pillar of oncology care
Theranostics offer the unique ability to combine diagnostic imaging and targeted radiation treatment in a single therapeutic strategy.2 This novel approach is a significant contribution to recent developments in systemic therapies in oncology such as targeted therapy, immunotherapy, and cell and gene therapy.1
RLT began with the use of 131I, a radioactive isotope of iodine, to treat thyroid cancer and hyperthyroidism.3 Recent advancements in RLT include the use of 177Lu-labeled peptides and proteins.2
The information herein is intended to assist practitioners in providing appropriate care for patients when using radiopharmaceuticals. This information is not intended to establish, nor should it be used to establish, a legal standard of care. It is important to adhere to all applicable standards when handling and administering radiopharmaceuticals. Institutions are responsible for ensuring their compliance with all laws and regulations by establishing their own policies, procedures, and guidance. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific course of action, or any third-party organization referenced herein.